Skip to content

To establish a ready network of Clinical Trial Units in certain parts of India to promote good clinical research practice.

To establish a ready network of Clinical Trial Units across the National Cancer Grid to promote multi-centric collaborative research in the field of drug and device development.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/03/041027
Enrollment
1000
Registered
2022-03-11
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C189- Malignant neoplasm of colon, unspecified Health Condition 2: C20- Malignant neoplasm of rectum Health Condition 3: C509- Malignant neoplasm of breast of unspecified site Health Condition 4: C81-C96- Malignant neoplasms of lymphoid, hematopoietic and related tissue Health Condition 5: C23- Malignant neoplasm of gallbladder

Interventions

Intervention1: Not Applicable: Not Applicable

Sponsors

Biotechnology Industry Research Assistance Council BIRAC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients with confirmed diagnosis of lymphoma/ chronic myeloid leukemia / breast cancer / lung cancer / colorectal cancer who are being planned for treatment. Age more than 14yrs. Willing for participation in registry (the investigations, follow-up will be as per the treating doctor and will be recorded from Electronic Medical Records (EMR).

Exclusion criteria

Exclusion criteria: Patients who have come only for second opinion. Patients who have been planned for best supportive care only.

Design outcomes

Primary

MeasureTime frame
The data will be analyzed for the following factors (disease specific) at the periodic interval. 1- Gender distribution. 2- Median age at presentation (range) 3- Stage at presentation. 4- Sub type distribution 5- Frequency of molecular abnormalities 6- Treatment given 7- Response to therapy 8- Relapse / Progression / Site 9- Disease - free / progression-free / event - free survival 10- overall survival.Timepoint: 3 years

Secondary

MeasureTime frame
NilTimepoint: Nil

Countries

India

Contacts

Public ContactDr Manoj Gorade

Tata Memorial Hospital

manojgorade@gmail.com022241770004255

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026